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ost-Effectiveness of Screening With
-Type Natriuretic Peptide to Identify Patients
ith Reduced Left Ventricular Ejection Fraction
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arvin A. Konstam, MD,§ Lynne W. Stevenson, MD, Paul G. Shekelle, MD, PHD¶
alo Alto, Stanford, and Los Angeles, California; and Boston, Massachusetts
OBJECTIVES This study was designed to evaluate the cost-effectiveness of screening patients with a B-type
natriuretic peptide (BNP) blood test to identify those with depressed left ventricular systolic
function.
BACKGROUND Asymptomatic patients with depressed ejection fraction (EF) may have less progression to
heart failure if they can be identified and treated.
METHODS We used a decision model to estimate economic and health outcomes for different screening
strategies using BNP and echocardiography to detect left ventricular EF 40% for men and
women age 60 years. We used published data from community cohorts (gender-specific BNP
test characteristics, prevalence of depressed EF) and randomized trials (benefit from
treatment).
RESULTS Screening 1,000 asymptomatic patients with BNP followed by echocardiography in those
with an abnormal test increased the lifetime cost of care ($176,000 for men, $101,000 for
women) and improved outcome (7.9 quality-adjusted life years [QALYs] for men, 1.3
QALYs for women), resulting in a cost per QALY of $22,300 for men and $77,700 for
women. For populations with a prevalence of depressed EF of at least 1%, screening with
BNP followed by echocardiography increased outcome at a cost$50,000 per QALY gained.
Screening would not be attractive if a diagnosis of left ventricular dysfunction led to
significant decreases in quality of life or income.
CONCLUSIONS Screening populations with a 1% prevalence of reduced EF (men at age 60 years) with BNP
followed by echocardiography should provide a health benefit at a cost that is comparable to
or less than other accepted health interventions. (J Am Coll Cardiol 2004;43:1019–26)
© 2004 by the American College of Cardiology Foundationa
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deart failure (HF) is a major health problem in the U.S.,
ith 4,790,000 patients affected and 550,000 new cases each
ear (1). The incidence of HF rises sharply with age,
mplying a large increase in the burden of disease over the
ext 20 years as the U.S. population ages. Survival is dismal
ollowing the development of HF, with only 20% of men
ge 65 years and over surviving to 5 years following
evelopment of symptoms (1). Not surprisingly, there is
trong interest in preventing HF by identifying patients at
isk and treating them before symptoms develop (2).
Screening for depressed left ventricular (LV) systolic func-
ion already meets many of the criteria for a successful
creening program. The disease (LV dysfunction) is common
nd associated with significant morbidity or mortality. There is
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ngeles School of Medicine, Los Angeles, California; §Tufts-New England Medical
enter, Boston, Massachusetts; Brigham and Women’s Hospital, Boston, Massa-
husetts; and ¶Greater Los Angeles VA Healthcare System, Los Angeles, California.
lthough this study was supported by the Agency for HealthCare Research and
uality through a contract with the Southern California Evidence Based Practice, the
onclusions are not the official position of the Department of Health and Human
ervices. Dr. Heidenreich is supported by a Career Development Award from the
eterans Affairs Health Services Research and Development Service. Dr. Arthur M.
eldman acted as the guest editor for this article.tManuscript received September 12, 2003; accepted October 15, 2003.recognizable latent phase: Stage B HF as defined by the
merican College of Cardiology and the American Heart
ssociation (3). The disease is treatable during the latent
hase; angiotensin-converting enzyme (ACE) inhibitors im-
roved outcome in the Studies Of Left Ventricular Dysfunc-
ion (SOLVD) prevention trial (4). However, an important
riterion that has yet to be established before widespread
pplication can be recommended is that screening be cost-
ffective.
There are several candidate screening tests to detect
atients with depressed LV function. The gold standard is
irect imaging of the LV using contrast left ventriculogra-
hy, nuclear angiography, or echocardiography. A less costly
ut less accurate test is the recently developed blood test for
-type natriuretic peptide (BNP). The BNP is released
rimarily by the cardiac ventricles in response to abnormal
oading conditions (5). The test (currently priced near $30)
s available as a rapid bedside assay and has been shown to
ccurately determine if HF is the cause of dyspnea in
atients presenting to the emergency room (6). The BNP
as also been found to be elevated in asymptomatic patients
ith LV dysfunction (7). The purpose of this study was to
etermine if population screening for LV systolic dysfunc-
ion would be cost-effective.
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creening strategies. We examined four screening strate-
ies. The first strategy was BNP testing and, if abnormal,
chocardiography. Patients with an ejection fraction (EF)
40% are treated (ACE inhibitors) to prevent the devel-
pment of HF. The second strategy was BNP only, with
reatment based on the results. The third strategy was
chocardiography for all patients (treatment based on the
esults). The fourth strategy was not to screen for depressed
V function. Each test leads to one of four results (true
ositive, false positive, true negative, false negative). Pa-
ients with true and false positive test results are treated.
atients with false negative results are treated only when
F develops. Patients with true negative results have a
ormal age-specific life expectancy. False-positive patients
eceive a decrement in quality-adjusted survival to account
or side effects of treatment.
ecision model. We developed a decision model using
ATA software (Version 4.0, TreeAge Software, Boston,
assachusetts). We determined the lifetime health and
conomic outcomes for hypothetical cohorts of 60-year-old
en and women with: 1) depressed EF (40% or less) but no
istory of HF and treated with ACE inhibitors, 2) de-
ressed EF but no history of HF and no treatment until HF
eveloped, and 3) without depressed EF.
Each month, patients with a low EF and without a
istory of HF can remain asymptomatic, develop HF, or die
Fig. 1). Of those patients developing HF, we assumed 33%
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BNP  B-type natriuretic peptide
ECG  electrocardiogram
EF  ejection fraction
HF  heart failure
LV  left ventricular
QALY  quality-adjusted life year
SOLVD  Studies Of Left Ventricular Dysfunction
igure 1. State-transition model. Each year a patient can transition
etween one of four health states. Patients with depressed ejection fraction
EF) may be hospitalized during each year. Transition to heart failure for
atients with normal EF is not explicitly modeled, but is accounted forlsing age-specific medical costs and survival for the general population.ould be hospitalized during their initial episode of HF (4).
nce patients develop HF they can remain stable, be
ospitalized, or die during each time period. The model
ollows patients until all have died (age 120). Patients
ithout depressed EF are assumed to have an average
ge-specific mortality based on U.S. life table data (8).
evelopment of HF for patients without depressed EF is
ccounted for using age-specific medical costs and survival
or the general population.
est characteristics. The gender-specific sensitivity and
pecificity of BNP testing for detecting depressed LV EF
based on echocardiography) were obtained from a recent
eport from the Framingham Heart Study (9) (Table 1).
his study excluded patients with HF and used the
hionogi BNP assay with a threshold of 24 mg/dl for men
nd 34 mg/dl for women. The gender-specific prevalence of
isease was taken as the average of estimates from the
ramingham Heart Study and a population study from
ochester, Minnesota (10). Prevalence was defined as
oderate-severe dysfunction (EF 40%). In sensitivity
nalysis we examined Biosite BNP test-characteristics from
population survey in Rochester, Minnesota (threshold at
he 95th percentile for gender and age: 52 mg/dl for men
ge 55 to 64 years and 93 mg/dl for women age 55 to 64
ears) (11). In the base case we assumed nuclear angiogra-
hy was the gold standard for measurement of EF because
t was the predominant measure used to determine EF in
he SOLVD prevention study (4) (from which we based
enefit of ACE inhibitors). We assumed that echocardiog-
aphy would be slightly less accurate (sensitivity of 92% and
specificity of 96%) when compared to this standard (12),
ut examined a scenario in sensitivity analysis where echo-
ardiography had 100% accuracy.
ealth outcomes. We based rates for the development of
F and death for asymptomatic patients with and without
CE inhibitor treatment using published data from the
OLVD prevention trial (4). We used actual event rates
uring the four years of reported follow-up. To model
utcome after four years, we used an average of the yearly
vent rates weighted by the number of subjects still enrolled
t each year of follow-up. Using this method we estimated
hat the yearly rate of progression to symptomatic HF
ould be 6.5% for patients treated with ACE inhibitors and
.8% for those not treated. We used a similar method to
etermine the yearly relative risk of death (compared to the
eneral population) for patients with asymptomatic LV
ysfunction who are treated (2.9) and not treated (3.3) with
CE inhibitors. We assumed that 32% of patients would
ot be adherent to therapy on the basis of past trials of ACE
nhibitors for patients without symptomatic HF (13).
We used SOLVD treatment trial data to estimate hos-
italization and death rates for patients with HF treated
ith ACE inhibitors (14). We used actual event rates
uring the four years of reported follow-up for the SOLVD
reatment trial. To model outcome following four years of
iving with HF, we used an average of the yearly event rates
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March 17, 2004:1019–26 Cost-Effectiveness of Screening With BNPeighted by the number of subjects participating during
ach year of the trial. We assumed that survival with HF is
urther improved (relative risk 0.65) by the use of beta-
able 1. Model Inputs
Variable Baseline Value (R
ge at beginning of model 60 (60–80)
revalence of low ejection fraction (%)
Men 3.5 (0.1%–10
Women 0.45 (0.1%–10
robability of death during year (general population) Age- and gender-
elative risk of death compared to general
population for
Asymptomatic untreated patients 3.3 (1.0–4.0
Asymptomatic patients treated with ACE
inhibitors
2.9 (1.0–4.0
Symptomatic patients treated with ACE inhibitors 6.5 (3.0–9.0
Symptomatic patients treated with ACE inhibitors
and beta-blockers
4.9 (2.0–8.0
robability of transition during year from
asymptomatic to symptomatic for
Untreated patients 9.8% (5.0%–15
Treated patients 6.5% (5.0%–10
robability of hospitalization per year if symptomatic 11% (5%–30%
robability of hospitalization during first episode of
heart failure
33% (10%–50
ercent adhering to therapy 68% (50%–100
ALY weights for
Asymptomatic patients 0.865 (0.68–1
Symptomatic patients 0.710 (0–1.0
osts
Cost of ACE inhibitor: lisinopril (per yr) $226 ($200–$6
Cost of beta-blocker: carvedilol (per yr) $1,152 ($89–$1
Cost of hospitalization $5,574 ($4,000–$1
Cost of outpatient CHF management including
treatment with beta-blockers
$1,700 ($500–$3
Cost of additional testing for patients with
depressed left ventricular function
$2,200 (0–$3,0
Cost of general health expenditures (by age)
Cost of BNP $32 (10–100
Cost of two-dimensional echocardiography $420 (98–1,00
est characteristics
Sensitivity BNP 0.65 (0.53–0.7
Men (24 pg/ml) 0.80 (0.55–1.0
Women (34 pg/ml)
Specificity BNP 0.86 (0.84–0.8
Men (24 pg/ml) 0.90 (0.88–0.9
Women (24 pg/ml)
Sensitivity echocardiography 0.92 (0.9–1.0
Specificity echocardiography 0.96 (0.9–1.0
Deflation rate (by yr)
Annual discount rate for costs and utilities 3% (0%–6%
CE  angiotensin-converting enzyme; BNP  B-type natriuretic peptide; CHF lockers (15). This method estimated that the yearly relativeisk of death (compared to the general population) for
atients with symptomatic LV dysfunction was 4.9 when
reated with ACE inhibitors and beta-blockers.
) Ref. Comment
(4,9,10) Average of mean age from SOLVD trials Framingham,
MA, and Rochester, MN, cohorts
(9,10) Average of Framingham, MA, and Rochester, MN,
populations without a history of heart failure
c (8) U.S. life tables
(4) SOLVD Prevention data
(4)
(14) SOLVD Treatment data
(15) SOLVD estimate adjusted for further benefit of beta-
blockers in 70%
(4) Weighted average of SOLVD Prevention Trial data*
0.65 (additional benefit of beta-blockade)
(14) Weighted average of SOLVD Treatment Trial data
(4) SOLVD Prevention Trial data
(13) Summary from multiple randomized trials
(16) Time-trade-off method, collected from general
population, and visual analog scale from SOLVD
study
Average of 3 national pharmacy prices for lisinopril
20 mg QD. Range includes enalapril 10 mg BID
($384)
Average of 3 national pharmacy prices for carvedilol
25 mg BID. Lower bound is metoprolol 50 mg BID
($89).
) Includes average cost for DRG 127 ($5,058) using
Medicare cost-charge ratio, and physician visits for
5 days (CPT 99222, 99232, 99238, 99252) including
one consultation (99261)
(20,22) Includes cost of non–beta-blocker, ACE inhibitor
medications, office visits and diagnostic tests.
Estimate for possible evaluation of ischemic heart
disease
(18) For U.S. population
Average of Biosite and Bayer test costs including
equipment and technician costs for high volume
laboratory
Medicare reimbursement for CPT 93307, 93320, and
93325
(9) Framingham population without a history of heart
failure (Shionogi assay)
(12) Assumes nuclear angiography is the gold standard
Consumer Price Index, Medical Care
(17)
estive heart failure.ange
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Cost-Effectiveness of Screening With BNP March 17, 2004:1019–26tility value of 0.71 to each year of life for patients living
ith HF on the basis of prior studies using the time-tradeoff
tility of patient preferences in HF (16). Asymptomatic
atients were assumed to have a utility value of 0.87, also
ased on the time-tradeoff utility (16). We also examined a
cenario where the utility for being asymptomatic was 1
perfect health).
osts. As recommended by the Panel on Cost-Effectiveness
n Health and Medicine, we analyzed a reference case
ssuming a societal perspective by including all costs of
edical care (Table 1), including medical costs incurred due
o increased survival (17). Because HF survivors will incur
dditional costs for non-HF treatments, we assigned all
atients a yearly age-specific (decile) cost of medical care
ased on medical expenditures for residents of the U.S. (18).
o this baseline cost we added the costs of hospitalization of
F, ACE inhibitor treatment, and other outpatient HF
are. We adjusted all costs to 2001 dollars using the medical
omponent of the Consumer Price Index (Bureau of Labor
tatistics).
We determined costs for hospitalization by applying the
verage U.S. cost (from cost-to-charge ratios for Medicare
dmissions) for diagnosis-related group 127, and added to
his the Medicare-allowed charge for physicians visits of
ntermediate intensity (mean length of stay 5 days in 2000),
ncluding one consultation. For costs of ACE inhibitor
reatment (lisinopril 20 mg QD) we used an average price
rom three national U.S. pharmacies. We assumed carve-
ilol would be the beta-blocker used for HF treatment,
iven the results of the Carvedilol or Metoprolol European
rial in Patients With Chronic Heart Failure (COMET)
ndicating a survival benefit of carvedilol over metoprolol
artrate (19). We determined the cost of outpatient HF care
y using published estimates of resource use (20,21) with
djustments for treatment with additional medications
such as spironolactone). Costs and benefits were dis-
ounted at 3% per year (17).
The costs of two-dimensional echocardiography includ-
ng technical and professional components were obtained
rom Medicare-allowed charges for 2001. In sensitivity
nalysis we assumed that the Doppler and color Doppler
omponents of the study would not be performed as part of
screening echocardiogram. The cost of BNP ($32) was
able 2. Lifetime Costs and Outcomes for Each Screening Strate
Strategy
Cost
(millions)
Incremental
Cost Life-Years
Increm
Life-
o screen $40.724 13,860.2
NP then echo $40.900 $176,000 13,867.7 7
NP alone $41.400 $500,000 13,867.1 4
cho alone $41.394 $494,000 13,871.4 3
ncremental costs and quality adjusted life years (QALYs) are ordered by cost and co
ear.
BNP  B-type natriuretic peptide.ased on the average cost of testing for the Biosite and bayer BNP test. We estimated the costs of BNP testing
ssuming 5,000 tests were done per year per laboratory:
hlebotomy and technician time ($9); reagent, calibration,
ontrols (if applicable), and maintenance ($22); and equip-
ent rental ($1). Lower volume laboratories will have a
igher cost per test; we therefore examined costs up to $100
er test in sensitivity analysis.
A diagnosis of depressed EF may lead to additional tests
stress testing, angiography). Therefore, we added $2,200 in
est costs for each patient with a positive test result assuming
00% would undergo stress echocardiography and 50%
ould receive coronary angiography. Because the benefit of
his additional testing is difficult to quantify, we made the
onservative assumption (biased against screening) that
dditional testing provided no additional benefit.
trategy comparisons. For each analysis we first rank the
trategies by increasing cost. We then compare the cost-
ffectiveness of the first strategy with the strategy that has
he next highest cost. Strategies that provide less effective-
ess at a higher cost are eliminated (dominated).
ensitivity analysis. We varied all parameters through the
anges listed in Table 1. Although there is no universally
ccepted threshold for cost-effectiveness (17), $50,000 per
ALY gained is commonly used (22). We also varied
ultiple parameters simultaneously using a Monte Carlo
nalysis with 5,000 simulations. Each parameter was as-
igned a distribution (beta-distribution for probabilities,
og-normal for other parameters including costs). Because
ittle data are available for assigning a variation to each
istribution, we chose a standard deviation equal to the
ean for cost variables. For parameters that are probabili-
ies, we chose a standard deviation that approximated the
ange given in Table 1 (2.5% lower bound to 97.5% upper
ound).
ole of the funding source. The Agency for Health Care
esearch and Quality provided funds but had no role in
odel construction, data analysis, or report preparation.
ESULTS
ase-case results: men. For a population of men age 60
ears with no history of HF (prevalence of low EF 3.5%) we
ound that a strategy of initial screening with BNP followed
r a Cohort of 1,000 Men
l
Incremental
Cost-Effectiveness
$/Life-Years
Quality-
Adjusted
Life-Years
Incremental
Quality-
Adjusted
Life-Years
Incremental
Cost-
Effectiveness
$/QALY
11,973.5
$ 23,500 11,981.4 7.9 $ 22,300
Dominated 11,981.0 4.4 Dominated
$133,500 11,985.4 4.0 $123,500
d to the prior non-dominated strategy. Costs and life years are discounted at 3% pergy fo
enta
Years
.5
.3
.7
mparey echocardiography improved outcome at a cost of $22,300
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March 17, 2004:1019–26 Cost-Effectiveness of Screening With BNPer QALY gained compared to no screening (Table 2). If
uality of life is ignored, BNP screening still costs only
23,500 per life-year gained compared to no screening. The
umber of men needed to screen with BNP was 44 to
dentify one with depressed EF, 133 to gain one year of life,
nd 127 to gain one QALY.
Screening with echocardiography was less attractive, with
n incremental cost-effectiveness compared to initial BNP
creening of more than $100,000 per QALY gained.
creening with BNP alone was more expensive and led to
orse outcome (dominated) compared to BNP testing
ollowed by echocardiography.
ase-case results: women. For a population of women age
0 years with no history of HF (prevalence of low EF
.45%), initial screening with BNP followed by echocardi-
graphy improved outcome at a cost of $77,700 per QALY
$91,800 per life-year) gained compared to no screening
Table 3). The number of women needed to screen was 278
o identify one with depressed EF, 909 to gain one year of
ife, and 769 to gain one QALY. Screening women with
chocardiography or BNP alone was dominated by BNP
creening followed by echocardiography. The BNP-alone
trategy is not discussed further.
ensitivity analyses. We tested the robustness of our
ase-case findings by varying each of the assumptions in
able 1 over the ranges listed. The decision to screen was
ensitive to the prevalence of low EF and the accuracy of the
creening tests. The model was insensitive to the benefit of
CE inhibitor treatment, costs of care, and cost of screen-
ng including echocardiography and BNP testing. We
erformed a probabilistic sensitivity analysis where the
arameters were replaced with distributions and random
ampling of each distribution was performed for 5,000
imulations. Screening men with BNP followed by echo-
ardiography compared to no screening cost $50,000 per
ALY gained in 88% and$100,000 per QALY gained in
8% of simulations. For women, screening with BNP
ollowed by echocardiography compared to no screening
ost $50,000 per QALY gained in 27% and $100,000
er QALY gained in 72% of simulations. Details of selected
ensitivity analyses are described in the following text.
revalence of depressed LV function. For the base-case
nalysis we assumed an asymptomatic population of men
able 3. Lifetime Costs and Outcomes for Different Screening S
Strategy
Cost
(Millions)
Incremental
Cost Life-Years
Incre
Life
o screen $46.860 15,962.0
NP then echo $46.961 $101,000 15,963.1
NP alone $47.367 $406,000 15,962.2 
cho alone $47.476 $515,000 15,963.0 
ncremental costs and quality-adjusted life years (QALYs) are ordered by cost and co
ear.
BNP  B-type natriuretic peptide.nd women (mean age 60 years) would be screened. If the lrevalence of low EF is at least 1% then the incremental
ost-effectiveness of BNP screening is $50,000 or less per
ALY gained for both men and women (Fig. 2). For the
ost-effectiveness ratio with BNP screening to be $20,000
er QALY gained, the prevalence must be 3% for women
nd 4% for men. Screening all patients with echocardiog-
aphy costs$50,000 per QALY gained if the prevalence of
epressed EF is at least 9% for men and 14% for women.
est characteristics. For our base case we chose the BNP
hreshold from the Framingham Heart Study that maxi-
ized the sums of sensitivity and specificity (21 ng/dl for
en and 34 ng/dl for women, Shionogi assay). If we use
NP test characteristics from Rochester, Minnesota (sen-
itivity 80% for men, 100% for women; specificity 86% for
en, 92% for women) (11) that used a threshold at the 95th
ercentile for the Biosite assay (52 ng/dl for men, 93 ng/dl
or women), the cost-effectiveness of screening is more
ttractive for men ($19,500 per QALY gained) and women
$63,600 per QALY gained).
If the accuracy of echocardiography is equal to radionu-
lide or contrast echocardiography for determination of EF
sensitivity and specificity 100%), then screening men with
NP becomes more attractive ($18,100 per QALY gained
ompared to not screening). However, screening all men
ith echocardiography becomes more attractive as outcome
s improved over initial BNP screening at a cost of $75,700
er QALY gained. For women, BNP screening would cost
ies for a Cohort of 1,000 Women
al
s
Incremental
Cost-Effectiveness
$/Life-Years
Quality-
Adjusted
Life-
Years
Incremental
Quality-
Adjusted
Life-Years
Incremental
Cost-
Effectiveness
$/QALY
13,802.8
$91,800 13,804.1 1.3 $77,700
Dominated 13,803.3 0.8 Dominated
Dominated 13,804.1 0 Dominated
d to the prior non dominated strategy. Costs and life years are discounted at 3% per
igure 2. Impact of prevalence of low ejection fraction (EF) (40%) on
he cost-effectiveness (C-E) of screening for men and women using B-type
atriuretic peptide (BNP) followed by echocardiography in those with a
ositive test. The cost-effectiveness ratio drops below $100,000 per
uality-adjusted life year (QALY) gained at a prevalence over 0.5% and
rops below $50,000 at a prevalence over 1%. For any given prevalence of
isease the cost-effectiveness ratio is lower for women because the accuracy
f BNP is slightly greater for women then men (9). Open circles  men
BNP vs. no screen); closed circles  women (BNP vs. no screen). LV trateg
ment
-Year
1.1
0.8
0.1
mpareeft ventricular.
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Cost-Effectiveness of Screening With BNP March 17, 2004:1019–2657,500 per QALY gained compared to no screening if
chocardiography had 100% accuracy.
ost of testing. Screening men with BNP remained eco-
omically attractive over a wide range of test costs (Fig. 3).
e assumed that the cost of echocardiography (including
wo-dimensional and Doppler) is $420. However, if only a
imited study (focused two-dimensional, no Doppler: $98)
ere required, screening first with BNP would cost $15,700
er QALY compared to no screening in men and $52,600
er QALY gained in women. At this reduced cost, echo-
ardiography compared to initial screening with BNP would
ost $55,600 per QALY gained for men but still be
ominated by initial BNP screening for women.
There may be unforeseen economic consequences of
abeling a patient with cardiac disease, such as difficulty
btaining insurance or employment. Screening would be
nattractive ($100,000 per QALY gained) if a diagnosis
ed to a loss of lifetime income of $30,000 for males or
7,000 for females. However, if treatment delays the onset
f symptomatic HF, then a diagnosis may lead to an
ncrease in income.
ffectiveness of treatment. In the base case, we calculated
n increase in 0.56 QALYs for men and 0.59 QALYs for
omen with low EF taking ACE inhibitors while asymp-
omatic, compared with those that wait to start treatment
hen they develop HF. This may be an overestimate
ecause the SOLVD prevention trial, from which we based
ur estimate, may have included some patients with symp-
oms of HF (and more likely to benefit from ACE inhibi-
ors). However, we may have underestimated the benefit of
creening if beta-blockers provide a benefit when used in
onjunction with ACE inhibitors to prevent HF (23). We
xamined a scenario where the addition of carvedilol in-
reased survival by 0.66 QALYs for women and 0.78
ALYs for men (assumes a relative mortality risk of 0.7
ith beta-blockade) (23). Screening with BNP remained
ost-effective for men ($21,300 per QALY gained) and
ecame more attractive for women ($63,800 per QALY
ained) compared to no screening.
ge at screening. Although the prevalence of low EF
igure 3. The impact of B-type natriuretic peptide (BNP) test price (base
ase $32) on the cost-effectiveness (C-E) of screening with BNP followed
y echocardiography is shown. At all BNP costs up to $100, screening men
ith BNP followed by echocardiography costs $35,000 per quality-
djusted life year (QALY) gained compared to not screening. Circles 
en; squares  women.ncreases with age (10), the potential benefit from treatment may decrease because of shorter life expectancy. The overall
ffect is that screening becomes slightly more attractive for
omen and remains attractive for men at older ages.
creening 80-year-old men with a prevalence of reduced EF
f 4% would cost $27,306 per QALY gained, whereas
creening 80-year-old women with a prevalence of reduced
F of 1.1% would cost $63,450 per life year gained.
CE inhibitor use in healthy patients. We assumed a
mall decrement in quality-adjusted survival (0.001 years or
.37 days per patient) to account for potential side effects of
CE inhibitor treatment and for possible increased stress of
eing labeled as someone with cardiac disease. We know of
o studies that have evaluated healthy persons’ preferences
or quality of life versus length of life with ACE inhibitor
se, so the negative health impact of taking unneeded
edication is unclear. However, our findings were largely
nchanged over a wide range of quality-of-life decrements
or ACE inhibitor treatment. The cost-effectiveness of BNP
creening compared to no screening in men ranged from
22,000 per QALY gained if there was no decrease in
uality-adjusted survival to $41,400 per QALY gained if
here was a thirty-day reduction in quality adjusted survival
er person.
epeated screening. If we assume that new-onset HF
incidence 0.4% for women age 60 to 69 years and 1% for
en age 60 to 69 years (24) is due to low EF in 50% (25),
hen an estimate of the incidence of asymptomatic low EF
s 0.2% per year for women and 0.5% per year for men age
0 to 69 years. If these incidence rates are correct, then
early screening would be expensive for both men ($113,200
er QALY gained) and women ($174,500 per QALY
ained). Repeat screening of men in their 60s would be
$50,000 per QALY gained if screening occurred every
hree years.
ISCUSSION
dentifying patients with depressed LV function is impor-
ant because there is treatment available (such as ACE
nhibitors) that is likely to prevent the progression to HF
4). Although screening for depressed ventricular function
as been considered (2,26), it has generated little enthusi-
sm, in part because a cost-effective screening test has not
een identified. Our study suggests that BNP testing
ollowed by echocardiography is a cost-effective screening
trategy for men and possibly women at age 60 years.
lthough BNP has only moderate sensitivity and specificity
ompared to echocardiography for identifying LV dysfunc-
ion (9), we found that for every 125 men screened, one year
f life would be gained at a cost of $23,500. This is
omparable to the estimated $16,000 cost per life year
ained with annual mammography for women age 50 to 79
ears (27).
The cost-effectiveness of screening was highly sensitive to
he prevalence of depressed EF. This explains why screening
en (prevalence 3.5%) was more economically attractive
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March 17, 2004:1019–26 Cost-Effectiveness of Screening With BNPhan screening women (prevalence 0.45%). Our analysis
ndicates that screening with BNP will cost $50,000 per
ALY gained if the prevalence is at least 1%. Although we
sed the gender specific prevalence of disease from popula-
ions within the U.S. (Framingham, Massachusetts; and
ochester, Minnesota), studies from Europe are consistent
ith these estimates. Davies reported a prevalence of
symptomatic low EF (40%) of 1% in primary care
atients age 45 years and greater (28). Data from commu-
ity cohorts in Scotland have found a 5% prevalence of
epressed EF in the general population over age 55 years
29). One-half of these patients were asymptomatic, sug-
esting that as a group they would benefit from screening
ith BNP (prevalence of asymptomatic low EF of 2% to
%).
Other populations will have a higher prevalence of
epressed EF, and screening these groups should be highly
ost-effective. Patients with prior atherosclerosis as mani-
ested by cerebrovascular accidents, transient ischemic at-
acks, or peripheral vascular disease had a 28% prevalence of
epressed EF with 44% being asymptomatic (30). Patients
ith a prior history of ischemic heart disease had a 12.1%
revalence of EF of 30% or less. Although some of these
atients will already be treated with ACE inhibitors (where
dditional treatment may not improve outcome), screening
hould be considered for those untreated.
We based our gender-specific sensitivity and specificity of
NP screening on the Framingham population (9), which are
ess favorable than data from other community studies. A
eport from Rochester, Minnesota, compared the Biosite and
hionogi BNP assays and found that using the 95th percentile
hreshold for the Biosite assay (52 ng/dl for 60-year-old men,
3 ng/dl for 60-year-old women) led to a sensitivity 80% for
en and 100% for women (specificity 86% for men, 92% for
omen) (11). The Shionogi assay (also used by the Framing-
am study) had lower sensitivities (50% for men, 50% for
omen) but higher specificities (92% for men, 94% for
omen). Because the Rochester random sample of the com-
unity included some symptomatic patients, it may not be
epresentative of an asymptomatic population. However, even
hen the better test characteristics from Rochester were used
n the analysis, the cost-effectiveness of screening improved
nly slightly for both men and women. Thus, the cost-
ffectiveness of screening was only mildly sensitive to the
ariation in test characteristics.
In contrast to screening middle-age to elderly patients,
creening younger patients is economically unattractive.
hen two population studies from Great Britain are
ombined (28,29), only two of 840 (prevalence 0.24%)
symptomatic women age 45 to 54 years had depressed LV
unction. Among 257 asymptomatic men 45 years of age
nly one (prevalence 0.4%) had depressed LV function
28,29). The cost-effectiveness of screening with BNP
ompared to no screening for these younger populations
ould be more than $150,000 per QALY. Asymptomatic
atients with a normal electrocardiogram (ECG) are an- other group that may not be attractive to screen with BNP.
mong 676 patients with a normal ECG and without
ymptoms of HF, 5 (0.7%) had reduced EF (31).
Our conclusion, that screening men and perhaps women
ppears to be cost-effective when compared with other
edical interventions, is different from the conclusion of the
ramingham Heart Study on which we based many of our
ssumptions (9). The Framingham Study noted that BNP
as not an “optimal” diagnostic test for depressed ventric-
lar function, with which we agree. We confirmed that
elying on BNP alone to decide on treatment is not a
ost-effective strategy. However, when echocardiography is
sed to confirm positive BNP tests, screening appears to be
conomically attractive for certain patient groups.
tudy limitations. The study is limited by the absence of
ata on the effect of ACE inhibitors in patients with no
nown cardiac disease. We relied on estimates from the
OLVD prevention trial to estimate the benefit of ACE
nhibitors in asymptomatic patients. Although these pa-
ients were considered asymptomatic, this population came
hrough unknown routes to clinical attention for identifica-
ion of cardiac disease. Thus, their event rate is likely to be
igher, and the effect of ACE inhibitors greater than for
atients with unsuspected LV dysfunction. However, if
eta-blockers are shown to prevent HF, then we may have
nderestimated the potential value of screening.
Although we accounted for a quality-of-life decrement
or patients receiving a positive test, we may have underes-
imated the repercussions of a diagnosis of LV dysfunction.
n addition, there are financial consequences if the ability to
btain insurance and employment is limited. These issues
ill be most significant for young patients, where many
ositive test results will be false positives because of the low
revalence of disease.
We did not include the potential screening benefits of
dentifying diastolic dysfunction or significant valvular disease
hat may be found with BNP screening. These patients may
enefit from more aggressive treatment of hypertension or fluid
verload. To the extent that these interventions improve
uality of life or survival, including these benefits would make
creening more economically attractive. A recent meta-analysis
uggests that ACE inhibitors may be more effective for
symptomatic men than women with reduced LV function
ost myocardial infarction (32). If true for all patients with
epressed EF, this would further support screening for men,
ut in women only at high-risk for heart disease.
We did not evaluate other tests that have been used to
stimate LV function, such as chest radiography or electro-
ardiography. We did not consider chest radiography in our
nalysis because it has been found to have poor sensitivity in
etecting depressed EF and is more expensive than BNP
esting (33). A prior report from Scotland found that an
bnormal ECG (pathological Q waves, left bundle branch
lock, ST-segment depression, T-wave abnormalities, LV
ypertrophy, or atrial fibrillation or flutter) had a sensitivity
f 60% and a specificity of 82% for depressed EF (30% or
l
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Cost-Effectiveness of Screening With BNP March 17, 2004:1019–26ess) (29). Given the comparable cost of BNP and electro-
ardiography, BNP screening would be preferred given its
lightly better test characteristics. We did not evaluate other
lood tests such as pro-BNP (34) because data regarding
revalence and outcome were not available. Despite our
ositive findings with BNP, additional research should
ontinue to determine the most cost-effective test for
dentifying depressed LV EF.
In summary, we found that screening with BNP followed
y echocardiography in those with an abnormal test was
conomically attractive for 60-year-old men and possibly for
omen. Screening all patients with echocardiography was
xpensive, and relying on BNP alone to decide treatment
ed to higher cost and worse outcome compared to the
equential BNP-echocardiography strategy. In general,
creening with BNP followed by echocardiography is likely
o be economically attractive for patient groups with at least
1% prevalence of moderate or greater LV systolic dysfunc-
ion. Additional studies of BNP or other diagnostic tests for
ow EF in asymptomatic patients are needed to determine
he impact of population screening.
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